Advanced search
Start date
Betweenand
Related content


Role of the Saccharomyces cerevisiae antioxidant protein Ahp1 in the cellular response against oxidative stress

Full text
Author(s):
Thiago Giove Mitsugi
Total Authors: 1
Document type: Master's Dissertation
Press: São Paulo.
Institution: Universidade de São Paulo (USP). Instituto de Biociências (IBIOC/SB)
Defense date:
Examining board members:
Oswaldo Keith Okamoto; Jose Alexandre Marzagao Barbuto; Raquel de Melo Alves Paiva
Advisor: Oswaldo Keith Okamoto
Abstract

Gliomas are the most common Central nervous system (CNS) tumors around the globe, they represent up to 80% of all malignant brain tumors. Between the types of gliomas, glioblastomas multiforme (GBM) stand out as the most frequent and aggressive tumors. Currently available therapies for glioblastoma treatment are insufficient, relying on medical intervention and chemo/radiotherapy, which result in a mean overall survival of less than 2 years for these patients. The resistance to chemo/radiotherapy, as well as the ability of glioblastomas to relapse, are frequently attributed to the presence of cancer stem cells (CSC) in these tumors. Various therapies aim to specifically target glioma stem cells (GSC), based on its molecular and physiologic peculiarities. Immunotherapy has emerged as a promising approach to oncology with the studies using chimeric antigen receptors (CAR), which led to the approval of 6 CAR-T cell based therapies by the US FDA and the European Commission (EC) as of early 2023.The success in CAR-T cell therapy extensively relies on the design of the antigen receptors, and a appropriate designation of the tumoral target. In that sense the present study aims to explore the therapeutic potential of a CAR capable of specifically recognizing a tumoral antigen overexpressed in GSCs. These antigens have been used as GSC markers and it´s expression on these cells have been correlated with aggressiveness both in vivo and in vitro, highlighting its potential as a tumoral antigen. We designed a CAR that will be expressed on a T lymphocyte cell line, and we are going to evaluate the capability of these CAR-T cells to specifically target GSCs. (AU)

FAPESP's process: 21/00689-5 - Development of a chimeric antigen receptor for application on glioblastoma treatment
Grantee:Thiago Giove Mitsugi
Support Opportunities: Scholarships in Brazil - Master